Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Widening Treatment Options Among Adult Patients With HER2-overexpressing or Mutant Solid Cancers.

NCT07192068 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT07192068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07192068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Widening Treatment Options Among Adult Patients With HER2-overexpressing or Mutant Solid Cancers.
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Recruiting
Start date
October 30, 2025
Completion date
June 24, 2030
Enrollment
105 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma, endometrial, head & neck cancer, non-small cell lung cancer, sarcoma